Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
News > Business News
Audio By Carbonatix
1:01 PM on Thursday, February 12
The Associated Press
FREMONT, Calif.--(BUSINESS WIRE)--Feb 12, 2026--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ).
View source version on businesswire.com:https://www.businesswire.com/news/home/20260212390848/en/
CONTACT: Investor Relations:
Caroline Corner
415-202-5678Media:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Personalis, Inc.
Copyright Business Wire 2026.
PUB: 02/12/2026 04:01 PM/DISC: 02/12/2026 04:02 PM
http://www.businesswire.com/news/home/20260212390848/en
